Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Yep the list of negatives is longer than the list of positives especially when it comes to Regabatin, Rexista and PODRAS next potential phases of growth right!

And it goes without saying that the list of negatives on IPCI's entire generics pipeline is so long it makes the 2 positives pale in comparison even with quarter over quarter growth now underway in fiscal Q4 2017.

It looks like IPCI's 2017 revs are gonna come in at $6M minimum and should double to $12M at least next year...which represents excellent growth initiating from the $2M revs garnered last year.

But we've said it too many times to count...institutional money places no value on IPCI's generics at this stage so the focus needs to be on how the hell to attract institutional money into this stock right!